OTLC Stock Overview A clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Oncotelic Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Oncotelic Therapeutics Historical stock prices Current Share Price US$0.04 52 Week High US$0.044 52 Week Low US$0.017 Beta -0.29 1 Month Change 45.09% 3 Month Change 29.13% 1 Year Change 1.66% 3 Year Change -81.66% 5 Year Change -75.82% Change since IPO -63.73%
Recent News & Updates
Oncotelic Therapeutics, Inc. Implements PDAOAI Platform Jan 01
Oncotelic Therapeutics, Inc. announced delayed 10-Q filing Nov 15 Oncotelic Therapeutics, Inc. announced delayed annual 10-K filing Apr 02
Oncotelic Therapeutics, Inc. Announces Linkage of Cancer and Lupus in Gliomas Patients Mar 27
Oncotelic Therapeutics, Inc. announced delayed 10-Q filing Aug 17
Oncotelic Therapeutics, Inc. announced delayed 10-Q filing May 16 See more updates
Oncotelic Therapeutics, Inc. Implements PDAOAI Platform Jan 01
Oncotelic Therapeutics, Inc. announced delayed 10-Q filing Nov 15 Oncotelic Therapeutics, Inc. announced delayed annual 10-K filing Apr 02
Oncotelic Therapeutics, Inc. Announces Linkage of Cancer and Lupus in Gliomas Patients Mar 27
Oncotelic Therapeutics, Inc. announced delayed 10-Q filing Aug 17
Oncotelic Therapeutics, Inc. announced delayed 10-Q filing May 16
Oncotelic Announces Initiation of Clinical Study in Non-Small Lung Cell Cancer Feb 07
Oncotelic Therapeutics, Inc. Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic Cancer Jan 26
Oncotelic Therapeutics, Inc. Presents Clinical Data of Confirming TGF-BETA>2 as the Appropriate Target for Gliomas At JCA-AACR Meeting 2022 Dec 20
Oncotelic Therapeutics, Inc. announced delayed 10-Q filing Nov 15
Oncotelic Initiates Clinical Trials Evaluating OT-101 Against Pediatric Gliomas Nov 09 Oncotelic Therapeutics, Inc. announced delayed 10-Q filing Aug 16
Oncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Mesothelioma (M201) May 26
Oncotelic Therapeutics, Inc. announced delayed 10-Q filing May 17
Oncotelic Appoints Seymour Fein M.D. as Chief Regulatory Officer May 05
Oncotelic Therapeutics, Inc. Appoints Fatih Uckun as Chief Medical Officer May 04
Oncotelic Therapeutics, Inc. announced delayed annual 10-K filing Apr 01
Oncotelic Presenting OT-101 Oncology Program at Biotechgate Digital Partnering Jan 20
Oncotelic Therapeutics, Inc. Initiates Phase 1 Trial Evaluating CA4P in Combination with Pembrolizumab for Melanoma Jan 07
Oncotelic Announces ORF8 Mutations are Driving the Evolution of the Delta and the Omicron Variants Dec 23 Oncotelic Therapeutics, Inc. announced that it has received $0.5 million in funding from Talos Victory Fund, LLC, Mast Hill Fund, L.P.
Oncotelic Announces Positive Topline Data for OT-101 C001 COVID Study Nov 24
Oncotelic Therapeutics, Inc. Reports PulmoHealTM/ ArtiVedaTM Proven Active against Mild and Moderate COVID-19 Following the Preplanned Prospective Analysis of ARTI-19 Clinical Trial Aug 25
Oncotelic Therapeutics, Inc. announced delayed 10-Q filing Aug 17
Oncotelic Therapeutics, Inc. announced that it has received $0.6985 million in funding from Autotelic Inc. Aug 06
Oncotelic Therapeutics, Inc. Closes Covid-19 Clinical Trial Early Jun 16
Oncotelic Therapeutics, Inc. announced delayed 10-Q filing May 18
Oncotelic Therapeutics, Inc. announced delayed annual 10-K filing Apr 03
Mateon Announces Initiation of Phase 1B Clinical Trial on OT-101/IL-2 Combination Therapy for Solid Tumors Mar 16
Mateon Therapeutics, Inc. Announces Enrollment Enrollment of its Sentinel Part 1 and Part 2 COVID-19 Mar 10
Mateon Therapeutics, Inc. and Windlas Biotech Limited Launches Pulmoheal™, A Combined Lung Therapy and Ai Telemedicine 360° Solution Feb 23
Mateon Therapeutics, Inc. Partners with The Chopra Foundation for Development of PulmoHea and ARTIVeda Feb 18
Mateon Therapeutics, Inc. Announces Completion of Arti-19 and Publication of Positive Interim Data Feb 04
Mateon Therapeutics, Inc. Launches its Artificial Intelligence Telemedicine Platform for Post Marketing Survey to Support the Launch of its Drug Product, PulmoHealTM Feb 02
Mateon Announces Positive Interim Results from ARTI-19 Clinical Trial Evaluating Covid-19 Therapeutic Jan 14
Mateon Therapeutics and Windlas Biotech Enter into Definitive Agreement to Commercialze Artiveda™ Against Covid-19 Nov 12
Mateon Therapeutics, Inc. Announces the Receipt of Approval from Instituto Nacional De Salud (Ins), the Regulatory Agency of Peru, to Initiate the Company’s C001- Phase 2 Clinical Trial of OT-101 Nov 06
Mateon Therapeutics, Inc. Receives Approval from Republica Argentina for Phase 2 Global Study for OT-101 Oct 20
Mateon Therapeutics, Inc. Announces First Patient Enrolled in ARTI-19: A Multicenter Interventional Study of ArtiShield Against COVID-19 Oct 08
Mateon Therapeutics, Inc. and Windlas Biotech Limited Announce ArtiShield Is Now Approved for Manufacture and Marketing by the Ministry of AYUSH Oct 06 Mateon Therapeutics, Inc. announced that it has received $2 million in funding Jun 30
Shareholder Returns OTLC US Biotechs US Market 7D 12.2% 0.4% 1.5% 1Y 1.7% -2.7% 22.4%
See full shareholder returns
Return vs Market: OTLC underperformed the US Market which returned 22.4% over the past year.
Price Volatility Is OTLC's price volatile compared to industry and market? OTLC volatility OTLC Average Weekly Movement 22.7% Biotechs Industry Average Movement 11.1% Market Average Movement 5.9% 10% most volatile stocks in US Market 18.1% 10% least volatile stocks in US Market 3.0%
Stable Share Price: OTLC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: OTLC's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. It develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company also develops OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Show more Oncotelic Therapeutics, Inc. Fundamentals Summary How do Oncotelic Therapeutics's earnings and revenue compare to its market cap? OTLC fundamental statistics Market cap US$16.25m Earnings (TTM ) -US$4.66m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) OTLC income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$4.66m Earnings -US$4.66m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.011 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio 159.1%
How did OTLC perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/17 09:48 End of Day Share Price 2025/02/14 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Oncotelic Therapeutics, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Theodore O'Neill Litchfield Hills Research, LLC
